Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
4 Cards in this Set
- Front
- Back
|
Bonner RCT 2006. Cetuximab for Head and Neck Cancer: Inclusion/Exclusion Criteria.
|
Stage III/IV larynx, hypopharynx, larynx, KPS of 60 or better, normal hematopoetic and renal function. Excluded if previous cancer. EGFR staining of tumors was not assessed.
|
|
|
Eich 2010, GHSG, HD 11: RCT for tx of Unfavorable Hodgkins Lymphoma: Inclusion/Exclusion criteria
|
1. Hodgkins lymphoma, biopsy proven
2. Stage IA, IB, IIA with atleast 1 of the following risk factors: extranodal involvement ESR 50 or more ESR 30 or more with B symptoms 3 or more lymph node areas Bulky mediastinal mass > 1/3 MTTD 3. IIB with ESR 50 or more, 30 or more with B symptoms. 3 or more LN areas: neither: bulky mediastinal mass or extranodal involvement allowed |
|
|
Eich 2010, GHSG, HD 11: RCT for tx of Unfavorable Hodgkins Lymphoma: Arms
|
A. 4 x ABVD, 30 Gy of IFRT
B. 4 x ABVD, 20 Gy of IFRT C. 4 x BEACOPP, 30 GY of IFRT D. 4 Cycles of BEACOPP, 20 Gy of IFRT |
|
|
Eich 2010, GHSG, HD 11: RCT for tx of Unfavorable Hodgkins Lymphoma: Conclusions
|
1. Moderate dose escalation of chemotherapy did not improve the outcome. Patients with early unfavorable HL should be treated with ABVD x 4 cycles then 30 Gy IFRT.
2. ABVD x 4 cycles with 20 Gy of IFRT were inferior to the other arms in terms fo FFTF, implying a reductuin is only possible when combined with a more intensive regimen than ABVD. |
